Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
Details : UT-15C is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2014
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2013
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Three Times Daily Dosing of UT-15C
Details : UT-15C is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2012
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Remodulin® to Oral Treprostinil Transition
Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2012
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2012
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2012
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Details : Treprostinil Diolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2011
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2010
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2010
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
Details : Treprostinil Diethanolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2010
Lead Product(s) : Treprostinil Diolamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable